Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study

• Status: Unknown status
• Trial end date: 2019-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study mainly evaluate the clinical effect of Apatinib in the treatment of patients with pulmonary metastasis of hepatocellular carcinoma.Half of participants will receive Apatinib and transcatheter arterial chemoembolization (TACE) therapy in combination,while the other half will receive TACE therapy alone.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhejiang Cancer Hospital
• Collaborators: First Affiliated Hospital of Wenzhou Medical University; First Affiliated Hospital of Zhejiang University; Ningbo No.2 Hospital; Second Affiliated Hospital, School of Medicine, Zhejiang University; The Central Hospital of Lishui City
• Treatments: Apatinib; Chlorotrianisene

Criteria

Inclusion Criteria:

• clinical diagnosis of hepatocellular carcinoma

• refused to sorafenib treatment

• have at least one measurable pulmonary lesions

• expected survival time ≥ 12 weeks

Exclusion Criteria:

• within four weeks before the study received radiotherapy or chemotherapy

• With a variety of factors influencing oral drugs taking and absorption (such as unable to swallow, chronic diarrhea and intestinal obstruction)